"Development and Implementation of Novel Chatbot-based Genomic Research Consent".

Chatbot Consent Genetic counseling Genetic research Genetic testing

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
24 Jan 2023
Historique:
pubmed: 8 2 2023
medline: 8 2 2023
entrez: 7 2 2023
Statut: epublish

Résumé

To conduct a retrospective analysis comparing traditional human-based consenting to an automated chat-based consenting process. We developed a new chat-based consent using our IRB-approved consent forms. We leveraged a previously developed platform (Gia Engagement rates were similar between both consenting methods. The median length of the consent conversation was shorter for Gia users compared to traditional (44 vs. 76 minutes). Additionally, the total time from referral to consent completion was faster with Gia (5 vs. 16 days). Within Gia, understanding was assessed with a 10-question quiz that most participants (96%) passed. Feedback about the chat consent indicated that 86% of participants had a positive experience. Using Gia resulted in time savings for both the participant and study staff. The chatbot enables studies to reach more potential candidates. We identified five key features related to human-centered design for developing a consent chat. This analysis suggests that it is feasible to use an automated chatbot to scale obtaining informed consent for a genomics research study. We further identify a number of advantages when using a chatbot.

Identifiants

pubmed: 36747692
doi: 10.1101/2023.01.23.525221
pmc: PMC9900780
pii:
doi:

Types de publication

Preprint

Langues

eng

Déclaration de conflit d'intérêts

Competing Interests EDS, SKS, GMM, AHKK, and VAF are full time employees and stockholders of Invitae Corporation.

Auteurs

Erica D Smith (ED)

Invitae Corporation, San Francisco, CA, USA.

Sarah K Savage (SK)

Invitae Corporation, San Francisco, CA, USA.

E Hallie Andrew (EH)

Children's National Rare Disease Institute, Division of Genetics and Metabolism, Washington, DC, USA.
Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.

Gloria Mas Martin (GM)

Invitae Corporation, San Francisco, CA, USA.

Amanda H Kahn-Kirby (AH)

Invitae Corporation, San Francisco, CA, USA.

Jonathan LoTempio (J)

Institute for Clinical and Translational Science, University of California, Irvine, CA, USA.

Emmanuèle Délot (E)

Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.
Department of Genomics and Precision Medicine, George Washington University, Washington, DC, USA.

Andrea J Cohen (AJ)

Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.

Georgia Pitsava (G)

Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.

Seth Berger (S)

Children's National Rare Disease Institute, Division of Genetics and Metabolism, Washington, DC, USA.
Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.
Department of Genomics and Precision Medicine, George Washington University, Washington, DC, USA.

Vincent A Fusaro (VA)

Invitae Corporation, San Francisco, CA, USA.

Eric Vilain (E)

Center for Genetic Medicine Research, Children's National Research Institute, Washington, DC, USA.
Institute for Clinical and Translational Science, University of California, Irvine, CA, USA.
Department of Genomics and Precision Medicine, George Washington University, Washington, DC, USA.

Classifications MeSH